Developer docs
API playgroundTry for free, no card

Search company profiles

Maculaser

Full company profile

uuid0003tbf

Namestring
Maculaser
Legal namestring
Maculaser Oy
Websiteurl
maculaser.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Maculaser Oy is a clinical-phase, privately held Finnish medical technology company (incorporated in Finland, headquartered in Espoo, Helsinki metropolitan area) developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders. The platform is built on patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry, achieving approximately 0.6°C precision at the lesion threshold and enabling patient-specific, non-damaging exposure. The system uses a non-contact delivery lens, automated pupil tracking, and active over-heating detection, and operates on the principle that controlled local heating (around 44°C) activates the retina's natural defense mechanisms — including heat shock protein production, autophagy, and antioxidant stimulation — without structural damage. Targeted indications include age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), with the stated strategic intent of shifting treatment upstream from late-stage drug injections toward earlier, preventive intervention.

The technology originates from a 2013 research program at Aalto University, with the company itself founded in 2020. Maculaser holds five patent families with granted patents across the EU, US, and Japan (including JP 7475071 B2), and the core approach was validated in a 2025 peer-reviewed Nature Communications publication co-authored with Karolinska Institutet/St. Erik Eye Hospital and the University of Helsinki. The company is led by CEO and co-founder Jani Tirronen, CSO Teemu Turunen (PhD), CTO Jaakko Nieminen (PhD), and Head of Product Ossi Kaikkonen, supplemented by a Head of Regulatory Affairs/Quality Assurance and a Clinical Trial Manager hired in 2024.

Maculaser is pre-revenue and pre-commercial: its device is investigational use only, has not received FDA or CE clearance, and is not available for sale. The planned revenue model is hardware sales of the laser therapy system to ophthalmologists and eye care professionals, with a go-to-market approach centered on integrating an outpatient, repeatable procedure into regular eye-care workflows. Funding to date totals approximately €3M (public and private) as of 2023, with an additional undisclosed round co-led by ZEISS Ventures and M2Care announced in May 2026, plus non-dilutive support from Business Finland and the Instrumentarium Science Foundation, and participation in the €32M EU-funded PhotonMed initiative spanning 9 countries.

Short descriptiontext

Maculaser is a Finnish clinical-phase medical technology company developing a temperature-controlled retinal laser therapy platform using ERG-based thermal dosimetry to deliver personalized, non-damaging treatments for retinal disorders including AMD, DME, and CSC, targeting ophthalmologists and eye care professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
retinal laser therapy, ophthalmic medical devices, temperature-controlled laser, retinal disorder treatment, electroretinography dosimetry
Industry1 code
PRIMARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Ophthalmic Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Maculaser is developing a laser-based medical device for retinal treatment. As the technology progresses through clinical trials toward commercialization, the company plans to generate revenue through the sale of its temperature-controlled retinal laser therapy system to ophthalmologists and healthcare providers.

maculaser.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Maculaser is developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). The investigational medical device uses patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry to deliver personalized, non-damaging laser energy that activates the eye's natural cellular defense mechanisms. The platform integrates active retinal temperature monitoring, non-contact lens delivery, and automated pupil tracking, and is currently in clinical development for investigational use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Temperature-dosing precision of approximately 0.6°C at lesion threshold
+3 more records
Product overview1 text field

Maculaser offers a single unified product: its Temperature-Controlled Retinal Laser Therapy Platform. This medical device system provides personalized, non-damaging retinal treatment through controlled heat exposure that activates natural cellular defense mechanisms (heat shock protein production, autophagy, and antioxidant stimulation). The platform consists of temperature monitoring and control algorithms, a non-contact lens delivery system, and automated pupil tracking. The technology targets conditions including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), and is currently in clinical development with safety trials underway.

Product and service1 record
1Temperature-Controlled Retinal Laser Therapy Platform
CategoryOphthalmic Medical Devices
Description

An investigational retinal laser therapy system for healthcare providers (ophthalmologists and eye-care professionals) that delivers personalized, non-damaging temperature-controlled retinal heating to trigger the eye's natural heat-shock, autophagy, and antioxidant defense mechanisms. The platform is being developed for the treatment of retinal disorders including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). It is intended for investigational use only and is not yet approved or commercially available.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-17
Description

Maculaser is part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, Chips JU)-funded initiative spanning 9 countries. This ambitious collaboration brings together leading research institutes and industrial partners to advance healthcare with cutting-edge photonics-based solutions. Maculaser is integrating innovative photonic technologies into their treatment platform to enhance outcomes for patients with macular degeneration and other retinal conditions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration with Aalto University researchers who have been pioneers in retinal temperature monitoring and heat shock response research since 2013. University provided foundational research for Maculaser's core technology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborating researchers demonstrated that real-time electroretinography-based thermal dosimetry can activate cytoprotective pathways without retinal damage in preclinical pig model. Key partner in Nature Communications published research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborating institution in research demonstrating ERG-guided, temperature-controlled retinal laser study published in Nature Communications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lumenis, now part of Boston Scientific, was a major ophthalmic laser company with strong retinal laser franchises. Its historical positioning as a retinal laser incumbent targeting the same AMD/DME treatment use cases makes it a useful comparable for category economics.

TypeBroad incumbent
Description

Alcon is a global ophthalmic incumbent with broad surgical and vision-care device franchises. Its constellation of retinal surgical and vitrectomy platforms is sold to the same retinal specialists targeted by Maculaser, and Alcon is a benchmark for the scale of a fully built-out ophthalmic commercial operation.

TypeRegional player
Description

Optos, part of Nikon Healthcare, sells ultra-widefield retinal imaging diagnostics widely used by retinal specialists — overlapping but complementary to Maculaser. It is a regional/adjacent peer serving the same specialist channel with diagnostic rather than therapeutic devices.

TypeDirect peer
Description

Iridex is a direct peer that markets ophthalmic laser systems including the PASCAL and MicroPulse platforms used for retinal laser therapy (including subthreshold and pattern scanning approaches for DME and AMD). They are the closest comparable to Maculaser in retinal laser thermal-therapy positioning and target physician base.

TypeOthers
Description

Genentech/Roche markets Lucentis, a leading anti-VEGF injection for AMD and DME. As the incumbent drug therapy that Maculaser aims to treat upstream of, it is the most important indirect competitor and benchmarks the size of the market segment Maculaser hopes to divert into earlier laser intervention.

TypeBroad incumbent
Description

Quantel Medical (part of Lumibird) develops and markets ophthalmic laser systems including retinal photocoagulation lasers used by the same retinal specialists Maculaser targets. It is an incumbent in the retinal laser category with established global distribution.

TypeBroad incumbent
Description

Topcon is a broad incumbent in ophthalmic equipment, with a portfolio of retinal imaging, diagnostics, and laser photocoagulation devices sold to retinal specialists globally. Its established retina-laser product line competes with the same retinal specialist customer segment Maculaser targets.

TypeBroad incumbent
Description

Nidek manufactures a broad portfolio of ophthalmic devices including retinal photocoagulation and pattern-scan laser systems sold to eye-care professionals. It is a comparable incumbent in retinal laser therapy with overlapping physician-customers and clinical use cases (DME, AMD).

9Carl Zeiss Meditec
TypeBroad incumbent
Description

Carl Zeiss Meditec is the broad ophthalmic incumbent whose corporate venture arm (ZEISS Ventures) just invested in Maculaser. The peer relationship is asymmetric — ZEISS is a potential strategic acquirer/distributor — but its ophthalmic laser, surgical, and diagnostic portfolio targets the same retinal specialists and disease indications.

TypeOthers
Description

Regeneron markets Eylea, the leading anti-VEGF injection for AMD, DME, and diabetic retinopathy — the standard-of-care therapy that Maculaser's early-intervention positioning aims to displace. It is the dominant competitive alternative rather than a direct device peer, but its commercial scale benchmarks the opportunity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Maculaser

Ophthalmic Medical Devicesmaculaser.com

Maculaser is a Finnish clinical-phase medical technology company developing a temperature-controlled retinal laser therapy platform using ERG-based thermal dosimetry to deliver personalized, non-damaging treatments for retinal disorders including AMD, DME, and CSC, targeting ophthalmologists and eye care professionals.

What Maculaser does

Maculaser Oy is a clinical-phase, privately held Finnish medical technology company (incorporated in Finland, headquartered in Espoo, Helsinki metropolitan area) developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders. The platform is built on patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry, achieving approximately 0.6°C precision at the lesion threshold and enabling patient-specific, non-damaging exposure. The system uses a non-contact delivery lens, automated pupil tracking, and active over-heating detection, and operates on the principle that controlled local heating (around 44°C) activates the retina's natural defense mechanisms — including heat shock protein production, autophagy, and antioxidant stimulation — without structural damage. Targeted indications include age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), with the stated strategic intent of shifting treatment upstream from late-stage drug injections toward earlier, preventive intervention.

The technology originates from a 2013 research program at Aalto University, with the company itself founded in 2020. Maculaser holds five patent families with granted patents across the EU, US, and Japan (including JP 7475071 B2), and the core approach was validated in a 2025 peer-reviewed Nature Communications publication co-authored with Karolinska Institutet/St. Erik Eye Hospital and the University of Helsinki. The company is led by CEO and co-founder Jani Tirronen, CSO Teemu Turunen (PhD), CTO Jaakko Nieminen (PhD), and Head of Product Ossi Kaikkonen, supplemented by a Head of Regulatory Affairs/Quality Assurance and a Clinical Trial Manager hired in 2024.

Maculaser is pre-revenue and pre-commercial: its device is investigational use only, has not received FDA or CE clearance, and is not available for sale. The planned revenue model is hardware sales of the laser therapy system to ophthalmologists and eye care professionals, with a go-to-market approach centered on integrating an outpatient, repeatable procedure into regular eye-care workflows. Funding to date totals approximately €3M (public and private) as of 2023, with an additional undisclosed round co-led by ZEISS Ventures and M2Care announced in May 2026, plus non-dilutive support from Business Finland and the Instrumentarium Science Foundation, and participation in the €32M EU-funded PhotonMed initiative spanning 9 countries.

Maculaser firmographics

Firmographics
Name
Maculaser
Legal name
Maculaser Oy
Website
https://maculaser.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Maculaser is a Finnish clinical-phase medical technology company developing a temperature-controlled retinal laser therapy platform using ERG-based thermal dosimetry to deliver personalized, non-damaging treatments for retinal disorders including AMD, DME, and CSC, targeting ophthalmologists and eye care professionals.
Ownership category
akta.pro rank

Maculaser industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAJAJ
Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)

Keywords

  • Retinal laser therapy
  • Ophthalmic medical devices
  • Temperature-controlled laser
  • Retinal disorder treatment
  • Electroretinography dosimetry

Where Maculaser is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Maculaser business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Medical Device Sales: Maculaser is developing a laser-based medical device for retinal treatment. As the technology progresses through clinical trials toward commercialization, the company plans to generate revenue through the sale of its temperature-controlled retinal laser therapy system to ophthalmologists and healthcare providers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Maculaser product offering

Product offering

Core offering

Maculaser is developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). The investigational medical device uses patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry to deliver personalized, non-damaging laser energy that activates the eye's natural cellular defense mechanisms. The platform integrates active retinal temperature monitoring, non-contact lens delivery, and automated pupil tracking, and is currently in clinical development for investigational use.

Product overview

Maculaser offers a single unified product: its Temperature-Controlled Retinal Laser Therapy Platform. This medical device system provides personalized, non-damaging retinal treatment through controlled heat exposure that activates natural cellular defense mechanisms (heat shock protein production, autophagy, and antioxidant stimulation). The platform consists of temperature monitoring and control algorithms, a non-contact lens delivery system, and automated pupil tracking. The technology targets conditions including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC), and is currently in clinical development with safety trials underway.

Differentiator

Problem solved

Functional benefit

Products and services

  • Temperature-Controlled Retinal Laser Therapy Platform An investigational retinal laser therapy system for healthcare providers (ophthalmologists and eye-care professionals) that delivers personalized, non-damaging temperature-controlled retinal heating to trigger the eye's natural heat-shock, autophagy, and antioxidant defense mechanisms. The platform is being developed for the treatment of retinal disorders including age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). It is intended for investigational use only and is not yet approved or commercially available.

Quantifiable outcome

  • Temperature-dosing precision of approximately 0.6°C at lesion threshold
  • +3 more outcomes

Companies that use Maculaser

Customer profile

Segments2 records

Ideal customer profiles1 record

Maculaser technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Maculaser partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • PhotonMed InitiativeflagshipStrategic or Co-development Partner · 17 January 2025Maculaser is part of PhotonMed, a €32 million European Union (Chips Joint Undertaking, Chips JU)-funded initiative spanning 9 countries. This ambitious collaboration brings together leading research institutes and industrial partners to advance healthcare with cutting-edge photonics-based solutions. Maculaser is integrating innovative photonic technologies into their treatment platform to enhance outcomes for patients with macular degeneration and other retinal conditions.
  • Aalto UniversitycoreStrategic or Co-development PartnerResearch collaboration with Aalto University researchers who have been pioneers in retinal temperature monitoring and heat shock response research since 2013. University provided foundational research for Maculaser's core technology.
  • Karolinska Institutet / St. Erik Eye HospitalcoreStrategic or Co-development PartnerCollaborating researchers demonstrated that real-time electroretinography-based thermal dosimetry can activate cytoprotective pathways without retinal damage in preclinical pig model. Key partner in Nature Communications published research.
  • University of HelsinkicoreStrategic or Co-development PartnerCollaborating institution in research demonstrating ERG-guided, temperature-controlled retinal laser study published in Nature Communications.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Maculaser competitors and assessment

Company assessment

Broad incumbents

  • Lumenis (Boston Scientific): Lumenis, now part of Boston Scientific, was a major ophthalmic laser company with strong retinal laser franchises. Its historical positioning as a retinal laser incumbent targeting the same AMD/DME treatment use cases makes it a useful comparable for category economics.
  • Alcon: Alcon is a global ophthalmic incumbent with broad surgical and vision-care device franchises. Its constellation of retinal surgical and vitrectomy platforms is sold to the same retinal specialists targeted by Maculaser, and Alcon is a benchmark for the scale of a fully built-out ophthalmic commercial operation.
  • Quantel Medical (Lumibird Medical): Quantel Medical (part of Lumibird) develops and markets ophthalmic laser systems including retinal photocoagulation lasers used by the same retinal specialists Maculaser targets. It is an incumbent in the retinal laser category with established global distribution.
  • Topcon Healthcare: Topcon is a broad incumbent in ophthalmic equipment, with a portfolio of retinal imaging, diagnostics, and laser photocoagulation devices sold to retinal specialists globally. Its established retina-laser product line competes with the same retinal specialist customer segment Maculaser targets.
  • Nidek: Nidek manufactures a broad portfolio of ophthalmic devices including retinal photocoagulation and pattern-scan laser systems sold to eye-care professionals. It is a comparable incumbent in retinal laser therapy with overlapping physician-customers and clinical use cases (DME, AMD).
  • Carl Zeiss Meditec: Carl Zeiss Meditec is the broad ophthalmic incumbent whose corporate venture arm (ZEISS Ventures) just invested in Maculaser. The peer relationship is asymmetric — ZEISS is a potential strategic acquirer/distributor — but its ophthalmic laser, surgical, and diagnostic portfolio targets the same retinal specialists and disease indications.

Regional players

  • Optos (Nikon Healthcare): Optos, part of Nikon Healthcare, sells ultra-widefield retinal imaging diagnostics widely used by retinal specialists — overlapping but complementary to Maculaser. It is a regional/adjacent peer serving the same specialist channel with diagnostic rather than therapeutic devices.

Direct peers

  • Iridex Corporation: Iridex is a direct peer that markets ophthalmic laser systems including the PASCAL and MicroPulse platforms used for retinal laser therapy (including subthreshold and pattern scanning approaches for DME and AMD). They are the closest comparable to Maculaser in retinal laser thermal-therapy positioning and target physician base.

Others

  • Genentech (Roche): Genentech/Roche markets Lucentis, a leading anti-VEGF injection for AMD and DME. As the incumbent drug therapy that Maculaser aims to treat upstream of, it is the most important indirect competitor and benchmarks the size of the market segment Maculaser hopes to divert into earlier laser intervention.
  • Regeneron Pharmaceuticals: Regeneron markets Eylea, the leading anti-VEGF injection for AMD, DME, and diabetic retinopathy — the standard-of-care therapy that Maculaser's early-intervention positioning aims to displace. It is the dominant competitive alternative rather than a direct device peer, but its commercial scale benchmarks the opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Maculaser financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Maculaser leadership team

Management profile

Number of profiles

Profiles6 records

Maculaser funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Maculaser M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maculaser

What does Maculaser do?

Maculaser is developing a temperature-controlled retinal laser therapy platform for the treatment of retinal disorders such as age-related macular degeneration (AMD), diabetic macular edema (DME), and central serous chorioretinopathy (CSC). The investigational medical device uses patented temperature-controlled retinal heating combined with electroretinography (ERG)-based thermal dosimetry to deliver personalized, non-damaging laser energy that activates the eye's natural cellular defense mechanisms. The platform integrates active retinal temperature monitoring, non-contact lens delivery, and automated pupil tracking, and is currently in clinical development for investigational use.

Is Maculaser a public or private company?

Maculaser is a private company. It is classified as venture growth investor backed and is currently operating.

When was Maculaser founded?

Maculaser was founded in 2013. It employs 1 to 10 people.

Where is Maculaser based?

Maculaser is headquartered in Helsinki, Finland, in the Europe region.

How does Maculaser make money?

One revenue line is on record: medical Device Sales.

Who are Maculaser's main competitors?

Broad incumbents on record are Lumenis (Boston Scientific), Alcon, Quantel Medical (Lumibird Medical), Topcon Healthcare, Nidek and Carl Zeiss Meditec. Optos (Nikon Healthcare) is listed as a regional player. Iridex Corporation is listed as a direct peer. Others are Genentech (Roche) and Regeneron Pharmaceuticals.

Does Maculaser have an API?

No public API is recorded for Maculaser.

What industry is Maculaser in?

Maculaser's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAJ, Vitreoretinal Surgical Devices (Vitrectomy Systems, Endolaser, Illumination, Tamponades). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales